REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered And Includes At Least Nitrogen And Sulfur As Ring Members > 1,4-thiazines > Additional Hetero Ring Attached Directly Or Indirectly To The 1,4-thiazine By Nonionic Bonding Additional Hetero Ring Attached Directly Or Indirectly To The 1,4-thiazine By Nonionic BondingAdditional Hetero Ring Attached Directly Or Indirectly To The 1,4-thiazine By Nonionic Bonding patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027146 - Methods of treating nervous disorders The invention relates to compositions and methods for treating nervous disorders. More particularly, the invention relates to methods of treating amyloïd beta peptide-related disorders, particularly Alzheimer's disease, using Rac1 inhibitors. The invention may be used in mammalian subjects, particularly human subjects, at various stages of the disease, including disease onset. ... 02/01/07 - 20070027145 - Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases The present invention relates to compounds of the Formula (I): wherein Z is —NH—, —O— or —S—; R1 represents bromo or chloro; R3 represents C1-3alkoxy or hydrogen; R2 is selected from one of the following three groups: (i) Q1X1- wherein X1 and Q1 are as defined herein; (ii) Q15W3— wherein ... 01/18/07 - 20070015749 - Use of substituted pteridines for the treatment of respiratory diseases The invention relates to the use of pteridines for the treatment of inflammatory and obstructive respiratory complaints, preferably asthma or COPD, as well as pharmaceutical compositions containing these compounds. ... 01/11/07 - 20070010512 - Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs and pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein A, X, W and Y are substituents. The present invention also relates to methods for using such compounds. ... 01/11/07 - 20070010511 - Organic compounds Novel substituted piperidines of the general formulae (I) and (II) with the substituent definitions as explained in detail in the description are described. The compounds are suitable in particular as renin inhibitors and are highly potent. ... 01/04/07 - 20070004714 - Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity The present invention is directed to compounds of formulae (I and II) (wherein A, D, E, X, l, m, n and R1 through R18 are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2. ... 01/04/07 - 20070004713 - Therapeutic benimidazole compounds The invention relates to novel compounds having general formula (I) are useful as selective ER-β ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis or prostate cancer. ... 12/28/06 - 20060293316 - Hexahydro-pyrrolo-isoquinoline compounds Certain hexahydro-pyrrolo-isoquinoline compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases. ... 12/21/06 - 20060287306 - Compounds to treat alzheimer's disease useful in treating Alzheimer's disease and other similar diseases. ... 12/21/06 - 20060287305 - Antiparasitic artemisinin derivatives (endoperoxides) This invention relates to the use of certain C-10 substituted derivatives of artemisinin of general formula (I) in the treatment and/or prophylaxis of diseases caused by infection with a parasite, certain novel C-10 substitued derivatives of artemisinin, processes for their preparation and pharmaceutical compositions containing such C-10 substituted derivatives. The ... 12/14/06 - 20060281741 - Quinoline derivatives as antibacterial agents a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or a N-oxide form thereof, wherein R1 is hydrogen, halo, polyhaloC1-6alkyl, C1-6alkyl, Ar or Het; p is an integer equal to 1 or 2; R2 is C1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy or C1-6alkylthio; R3 is Ar, Het or Het1; ... 11/30/06 - 20060270666 - Quinoxaline derivatives as neutrophil elastase inhibitors and their use There are provided novel compounds of formula (I) wherein R1, R4, R5, G1, G2, L and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The ... 11/23/06 - 20060264427 - Dna-pk inhibitors the dotted lines represent two double bonds in the appropriate locations; and where Z is selected from S, O, C(═O), CH2 and NH are disclosed for use in inhibiting DNA-PK. ... 10/26/06 - 20060241107 - Androgen receptor modulators and methods of use thereof Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of agonizing the androgen receptor in a patient, and in particular ... 10/26/06 - 20060241106 - Isoxazole compounds as inhibitors of heat shock proteins Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: (A), (B) wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted ... 09/21/06 - 20060211690 - Microglia inhibitors for interrupting interleukin 12 and ifngamma-mediated immune reactions The invention describes the use of microglia inhibitors for the production of pharmaceutical agents that inhibit immune reactions that are mediated by monocytes, macrophages and T cells, and their use for treating T-cell-mediated immunological diseases and non-T-cell-mediated inflammation reactions. ... 09/14/06 - 20060205718 - Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are ... 09/14/06 - 20060205717 - Pyridodiazines as plant fungicides Fungicidal compounds of general formula (1) wherein R, R1, R2, W, X, Y and Z are as defined in the specification. ... 08/03/06 - 20060173000 - Substituted indolepyridinium as anti-infective compounds their N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites, wherein n is 1, 2 or 3; R1 is H, CN, halo, aminoC(═O), C(═O)OH, C1-4alkyloxyC(═O), C1-4alkylC(═O), mono- or di(C1-4alkyl)aminoC(═O), arylaminoC(═O), N-(aryl)-N—(C1-4alkyl)aminoC(═O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het, or Het2; R2 is H, C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl, C2-10alkenyl ... 07/27/06 - 20060166978 - Substituted beta carbolines which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IκB kinase is involved. ... 07/06/06 - 20060148794 - Quinoline derivatives as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity. ... 06/29/06 - 20060142279 - Treatment of latent tuberculosis a pharmaceutically acceptable salt, a quaternary amine, a N-oxide, a tautomeric form or a stereochemically isomeric form thereof wherein R1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2, 3 or 4; R2 is hydrogen, hydroxy, mercapto, alkyloxy, alkyloxyalkyloxy, ... 06/22/06 - 20060135514 - Pyrazolo[1,5-a]pyrimidine derivatives The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or ... 06/01/06 - 20060116373 - Substituted pteridines for the treatment of inflammatory diseases The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds. ... 06/01/06 - 20060116372 - Substituted pteridines for the treatment of inflammatory diseases The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds. ... 06/01/06 - 20060116371 - Substituted pteridines for the treatment of inflammatory diseases The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds. ... 06/01/06 - 20060116370 - Substituted pteridines for the treatment of inflammatory diseases The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds. ... 06/01/06 - 20060116369 - Certain compounds, compositions, and methods Compounds useful for treating cellular proliferative diseases are disclosed. ... 05/25/06 - 20060111348 - Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders. ... 05/04/06 - 20060094714 - Compounds and their use to treat diabetes and related disorders The invention relates generally to compounds described herein. More specifically, the invention relates to compounds and pharmaceutical compositions containing such compounds. Methods of the invention comprise administration of a compound of the invention for the treatment of diabetes and related disorders. ... 04/20/06 - 20060084645 - Novel pyrimidine compounds, process for their preparation and compositions containing them The present invention provides new heterocyclic compounds, particularly substituted pyrimidines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan. ... 04/13/06 - 20060079518 - Novel tyrosine kinase inhibitors and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes. ... 03/30/06 - 20060069090 - Triazine compounds aryl, or heteroaryl; each of R2, R4, and R5, independently, is Rc, halogen, nitro, nitroso, cyano, azide, isothionitro, SRc, or ORc; R3 is Rc, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, ORc, OC(O)Rc, SO2Rc, S(O)Rc, S(O2)NRcRd, SRc, NRcRd, NRcCORd, NRcC(O)ORd, NRcC(O)NRcRd, NRcSO2, CORc, C(O)ORc, or C(O)NRcRd; n is 0, 1, 2, ... 03/30/06 - 20060069089 - Fungicides Fungicidal compositions of the general formula (1): wherein one of W, X, Y and Z is N and the others are CR8; R8 is H, halo, C1-4 alkyl, C1-4 alkoxy or halo(C1-4)alkyl, provided that when X is CH, Z is N, R is NHNH2, R1 is phenyl and R2 is ... 03/02/06 - 20060046985 - Tetrahydro--4h-pyrido[1,2-a}pyrimidines and related compounds useful as hiv integrase inhibitors Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (A): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1, 2 or 3, and R1, R3, R4, R12, R14, R16, R30, R32, R34 and R36 are defined herein. These compounds are useful ... 02/09/06 - 20060030560 - Pyrimidine compounds each of R2 and R4 is H; R3 is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl; R5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; X is NRc; Y is covalent bond, CH2, C(O), C═N—Rc, C═N—ORc, C═N—SRc, O, S, S(O), S(O2), or NRc; ... 02/09/06 - 20060030559 - Diazole derivatives wherein A, E, R1, R2 and R3 are as defined in application and pharmaceutical compositions containing them. The invention also relates to use of such compounds for the treatment of diseases mediated by the metabotropic glutamate receptors (mGluR), such as anxiety, chronic and acute pain, protection against liver damage, urinary ... 02/02/06 - 20060025409 - Pyrimidine compounds aryl, or heteroaryl; each of R2 and R4, independently, is Rc, halogen, nitro, cyano, isothionitro, SRc, or ORc; or R2 and R4, taken together, is carbonyl; R3 is Rc, alkenyl, alkynyl, ORc, OC(O)Rc, SO2Rc, S(O)Rc, S(O2)NRcRd, SRc, NRcRd, NRcCORd, NRcC(O)ORd, NRcC(O)NRcRd; NRcSO2Rd, CORc, C(O)ORc, or C(O)NRcRd, R5 is H or ... 12/22/05 - 20050282804 - Process for preparing 10alpha-[4'-(s,s-dioxothiomorpholin-1'-yl)]-10-deoxo-10-dihydroartemisinin in which X is a halogen atom with thiomorpholine dioxide at a temperature in the range of −30° C. to +20° C. is provided. ... 11/10/05 - 20050250770 - Fused heterocyclic compounds This invention provides fused heterocyclic compounds, pharmaceutical compositions of, the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders. ... 10/27/05 - 20050239777 - Quinazoline derivatives and pharmaceutical compositions containing them wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, ... 10/06/05 - 20050222141 - Novel phenylalanine derivatives Specific phenylalanine derivatives and analogues thereof have an antagonistic activity to α4 integrin. They are used as therapeutic agents for various diseases concerning α4 integrin. ... 09/08/05 - 20050197335 - Indazole-carboxamide compounds as 5-ht4 receptor agonists The invention provides novel indazole-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. ... 08/18/05 - 20050182050 - Therapeutic heterocyclic compounds Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The ... 08/04/05 - 20050171099 - 3-(diheteroarylmethylene)-8-azabicyclo[3.2.1]octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives This invention is directed to 3-(diheteroarylmethylene)-8-azabicyclo[3.2.1] octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1] octane derivatives useful as δ-opioid, μ-opioid, or δ-opioid and μ-opioid receptor receptor modulators. Depending on their agonist or antagonist effect, the compounds are useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and ... 08/04/05 - 20050171098 - Mch antagonists and their use in the treatment of obesity The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, ... 07/28/05 - 20050165010 - Use of substituted pteridines for the treatment of respiratory diseases The invention relates to the use of pteridines for the treatment of inflammatory and obstructive respiratory complaints, preferably asthma or COPD, as well as pharmaceutical compositions containing these compounds. ... 07/21/05 - 20050159414 - Use of substituted pyrimido[5,4-d]pyrimidines for the treatment of respiratory diseases The invention relates to the use of pyrimido[5,4-d]pyrimidines for the treatment of inflammatory and obstructive respiratory complaints, preferably asthma or COPD, as well as pharmaceutical compositions which contain these compounds. ... 07/07/05 - 20050148581 - Novel mycobacterial inhibitors the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and ... 06/16/05 - 20050130960 - Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma Substituted [1,4]oxazino[2,3-g]indazols for lowering intraocular pressure and treating glaucoma are disclosed. ... 06/09/05 - 20050124611 - Compounds for the treatment of male erectile dysfunction This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome. ... 06/02/05 - 20050119258 - A1 adenosine receptor antagonists wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described. ... ### FreshPatents.com Support |